长春瑞滨联合顺铂加同步放化疗治疗中晚期鼻咽癌的临床研究.doc

《长春瑞滨联合顺铂加同步放化疗治疗中晚期鼻咽癌的临床研究.doc》由会员上传分享，免费在线阅读，更多相关内容在工程资料-天天文库。

1、诱导化疗联合同期放化疗治疗III、IVa期鼻咽癌的临床研究摘要：li的评价单纯放疗和诱导化疗联合同期放化疗治疗HI、IV"期鼻咽癌的毒副反丿应、临床疗效和对生存期的影响。方法统计2000年至2005年我院诊治III、IVa期鼻咽癌患者169例，其屮113例患者接受单纯根治性放疗（对照组），56例患者接受XVB联合DDP诱导化疗2周期后行根治性放疗，同期给予DDP每周方案化疗（研究组），两组患者进行临床疗效和毒副反应的比较，Kaplan-Meier法计算5年生存率和无瘤生存率。结果研究组的鼻咽肿瘤和

2、颈淋巴结完全消退率优于对照组（92.8%vs80.5%,85.7%vs72.6%P<0.05）o研究组和对照组的5年生存率和无瘤生存率分别为71.70%vs61.3%和56.6%vs47.6%,差异有统计学意义（P〈0.05）。研究组毒性反应增加，以骨髓抑制、胃肠反皿和口腔黏膜炎为主。结论诱导化疗联合同期放化疗可提高局部晚期鼻咽癌的临床疗效和生存率。毒副反应较大,但不煤响治疗进稈。关键词：鼻咽肿瘤；诱导化疗；同期化放疗;生存分析ClinicalstudyofInduetionChemotherap

3、yPlusConcurrentRadiochemotherapyintheTreatmentofstage111andIVaadvancedNasopharyngealCareinomaDONGChao,RENYan-xin,YANGRun-xiang,ZhuangLi,RENHong-xuan.1.DapartmentoFthesecondmedicaloncology,TheThirdAffiliatedHospitalofKunmingMedicalUniversity,Kunming650

4、018,China；2.DapartmentofheadandneckAbstract：objectiveToevaluatetheefficacyandtoxicityofradiotherapyaloneandinductionchemotherapyplusconcurrentchemoradiotherapyforstagelllandIVanasopharyngealcancer(NPC)andtocomparetheinfluenceonsurvivalrates.MethodsToa

5、nalysisclinicaldatasof169locallyadvancedNPCpatientsfrom2000to2005.56casesweretreatedtwocyclesofinductionchem()therapyfollowedbyconventionalradicalradiotherapyandconcurrentweeklycisplatinchemotherapy(studygroup)；113weretreatedwithradiotherapyalone(cont

6、rolgroup).Thetherapeuticresponseandadversereactionofthetwogroupswerecompared.The5-yearoverallanddisease-freesurvivalrateswereanalyzedbyKaplan-Meier.Resultsthecompleteresponseratesofthenasopharyngealcontrolandthecervical1ymphnodesco门trolinstudygroupwer

7、esuperiortothatincontrolgroup(92・8%vs80.5%,85.7%vs72・6%P<0.05).The5-yearoverallsurvivalratesinstudygroupandcontrolgroupwere71.7%and56.6%respectively.Thedisease-freesurvivalratesintwogroupswere61.3%and47.6%。The5-yearoverallanddisease-freesurvivalratesw

8、eresignificantlyhigherinstudygroupthanincontrolgroup(P<0.05).Theratesoftoxicityeffectinstudygroupwerehigherthanincontrolgroup,themaintoxicitywashematologicaltoxicties,gastrointestinalreactionandoralmucositis.ConclusionsTheinductionchemotherapy